The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

Health Technology Assessment

Volumn 10, Issue 1, 2006, Pages

  Loveman, E ^a   Green, C ^a   Kirby, J ^a   Takeda, A ^a   Picot, J ^a   Payne, E ^a   Clegg, A ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; PLACEBO; RIVASTIGMINE; CARBAMIC ACID DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; INDAN DERIVATIVE; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE;

ABDOMINAL DISEASE; ABDOMINAL PAIN; ABNORMAL DREAMING; ABRASION; ACCIDENTAL INJURY; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; ASTHENIA; BACKACHE; BEHAVIOR; BODY WEIGHT DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COGNITION; COMMON COLD; CONFUSION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COUGHING; DATA ANALYSIS; DATA BASE; DIARRHEA; DIGESTIVE SYSTEM DISEASE; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG COST; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; DYSPEPSIA; ECONOMIC EVALUATION; ECZEMA; FALLING; FATIGUE; FECES INCONTINENCE; FEVER; FLATULENCE; FLU LIKE SYNDROME; FLUSHING; FRACTURE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEART INFARCTION; HOSTILITY; HUMAN; INSOMNIA; MALAISE; MEDICAL EXPERT; MEDICAL LITERATURE; MEDICAL RESEARCH; MENTAL DISEASE; META ANALYSIS; MOOD; MUSCLE CRAMP; NATIONAL HEALTH SERVICE; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NOSE CONGESTION; OUTCOME ASSESSMENT; PAIN; PATIENT CARE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PNEUMONIA; PREDICTION; PUBLICATION; QUALITATIVE ANALYSIS; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; RESTLESSNESS; REVIEW; RHINITIS; SIDE EFFECT; SINUSITIS; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SWEATING; SYNCOPE; SYSTEMATIC REVIEW; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; URINE INCONTINENCE; VERTIGO; VOMITING; WEIGHT REDUCTION; AGED; COST BENEFIT ANALYSIS; ECONOMICS; EVIDENCE BASED MEDICINE; FEMALE; MALE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COST-BENEFIT ANALYSIS; DOPAMINE AGENTS; EVIDENCE-BASED MEDICINE; FEMALE; GALANTAMINE; GREAT BRITAIN; HUMANS; INDANS; MALE; MEMANTINE; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; PHENYLCARBAMATES; PIPERIDINES; TREATMENT OUTCOME;

EID: 33644658662     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta10010     Document Type: Review

References (198)

1. Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technol Assess 2001; 5(1).
2. Ritchie K, Lovestone S. The dementias. Lancet 2002;360:1759-66.
3. Fratiglioni L, De Ronchi D, Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging 1999;15:365-75.
4. Rocca WA, Hofman A, Brayne C, Breteler MM, Clarke M, Copeland JR, et al. The prevalence of vascular dementia in Europe: facts and fragments from 1980-1990 studies. EURODEM-Prevalence Research Group. Ann Neurol 1991;30:817-24.
5. Andreasen N, Blennow K, Sjodin C, Winblad B, Svardsudd K. Prevalence and incidence of clinically diagnosed memory impairments in a geographically defined general population in Sweden. The Pitea Dementia Project. Neuroepidemiology 1999;18:144-55.
6. Kalaria R. Similarities between Alzheimer's disease and vascular dementia.J Neurol Sci 2002;203:29-34.
7. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-44.
8. Sandson TA, Price B. Diagnostic testing and dementia. Neurol Clin 1996;14:45-59.
9. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54 (Suppl 5):Suppl-9.
10. Rocca WA. Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 prevalence findings. Ann Neurol 1991;30:381-90.
11. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992;42:473-80.
12. Gold G, Giannakopoulos P, Montes-Paixao JC, Herrmann FR, Mulligan R, Michel JP, et al. Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia. Neurology 1997;49:690-4.
13. Zekry D, Hauw JJ, Gold G. Mixed dementia: epidemiology, diagnosis, and treatment.J Am Geriatr Soc 2002;50:1431-8.
14. Gearing M, Mirra SS, Hedreen JC, Sumi SM, Hansen LA, Heyman A. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology 1995;45:t-6.
15. Hofman A, Rocca WA, Brayne C, Breteler MM, Clarke M, Cooper B, et al. The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Eurodem Prevalence Research Group. Int J Epidemiol 1991;20:736-48.
16. Jagger C, Clarke M, Stone A. Predictors of survival with Alzheimer's disease: a community based study. Psychol Med 1995;25:171-7.
17. Walsh J, Welch G, Larson E. Survival of outpatients with Alzheimer-type dementia. Ann Intern Med 1990; 113:429-34.
18. Pitt FA, Chilcott J, Golightly P, Sykes J, Whittingham M. A review of the use of donepezil in the treatment of Alzheimer's disease. Sheffield, Trent Institute for Health Services Research, Universities of Leicester, Nottingham and Sheffield. Guidance Notes for Purchasers. Report No. 97/09; 1997.
19. Evans D, Smith LA, Scherr P, Albert M, Funkenstein HH, Hebert L. Risk of death from Alzheimer's disease in a community population of older persons. Am J Epidemiol 1991;134:403-12.
20. UK Government Actuary's Department. Population by age last birthday by single year of age; England and Wales 2002. URL: http://www.gad.gov.uk/Population/index.asp?v=Principal&y= 2002&subYear=Continue. Accessed July 2004.
21. Copeland JR, McCracken CE, Dewey ME, Wilson KC, Doran M, Gilmore C, et al. Undifferentiated dementia, Alzheimer's disease and vascular dementia: age- and gender-related incidence in Liverpool. The MRC-ALPHA Study. Br J Psychiatry 1999;175:433-8.
22. Di Carlo A, Baldereschi M, Amaducci L, Lepore V, Bracco L, Maggi S, et al. Incidence of dementia, Alzheimer's disease, and vascular dementia in Italy. The ILSA Study.J Am Geriatr Soc 2002; 50:41-8.
23. Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol 2002;59:1737-46.
24. Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland JR, Dartigues JF, et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(Suppl 5):Suppl-5.
25. Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, Copeland JR, et al. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology 1999;53:1992-7.
26. Holmes C, Cooper B, Levy R. Dementia known to mental health services: first findings of a case register for a defined elderly population. Int J Geriatr Psychiatry 2004;10:875-81.
27. Banerjee S. Services for older adults. In Thornicroft.G, Szmukler G, editors. Textbook of community psychiatry. London: Oxford University Press; 2001. pp. 381-96.
28. Neal M, Briggs M. Validation therapy for dementia. Cochrane Database Syst Rev 2003; (3):CDO01394.
29. Grasel E, Wiltfang J, Kornhuber J. Non-drug therapies for dementia: an overview of the current situation with regard to proof of effectiveness. Dement Geriatr Cogn Disord 2003;15:115-25.
30. NICE Technology Appraisal Guidance - No. 19. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. London: NICE; 2003.
31. Lindesay J, Marudkar M, van Diepen E, Wilcock G. The second Leicester survey of memory clinics in the British Isles. Int J Geriatr Psychiatry 2002; 17:41-7.
32. Department of Health. National Service Framework for Older People. London: Department of Health; 2001.
33. Phipps AJ, O'Brien JT Memory clinics and clinical governance - a UK perspective. Int J Geriatr Psychiatry 2002;17:1128-32.
34. Marshall M. The challenge of looking after people with dementia (editorial). BMJ 2001;323:410-11.
35. Alzheimer's Disease Society. Community care assessment. URL: http://www.alzheimers.org.uk/After_diagnosis/PDF/ 418_communityAssess.pdf. Accessed 18 June 2004.
36. Ballard C, Fossey J, Chithramohan R, Howard R, Burns A, Thompson P, et al. Quality of care in private sector and the NHS facilities for people with dementia: cross sectional survey. BMJ 2001; 323:426-7.
37. Becker RE. Therapy of the cognitive deficit in Alzheimer's disease: the cholinergic system. In Becker RE, Giacobini E, editors. Cholinergic basis for Alzheimer therapy. Boston; MD: Birkhauser; 1991.
38. CRD. Undertaking systematic reviews of research on effectiveness. 4. York: Centre for Reviews and Dissemination; 2001.
39. Drummond M, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275-83.
40. Alderson P, Green S, Higgins J, editors. Cochrane reviewers' handbook 4.2.2 [updated March 2004]. In The Cochrane Library, Issue 1. Chichester: John Wiley; 2004.
41. Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P, et al. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Carr Med Res Opin 2002;18:347-54.
42. Feldman H. Gauthier S, Heckerj, Vellas B, Subbiah P, Whalen E, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease [published erratum appears in Neurology 2001;57:2153]. Neurology 2001;57:613-20.
43. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105-15.
44. Homma A, Takeda M, Imai Y, Udaka F, Hasegawa K, Kameyama M, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease: a 24-week, multicenter, double-blind, placebo-controlled study in Japan. Dement Geriatr Cogn Disord 2000;11:299-313.
45. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. AmJ Psychiatry 2003; 160:2003-11.
46. Molis RC, Doody RS, Morris JC, IeniJR, Rogers SL, Perdomo CA, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients [published erratum appears in Neurology 2001;57:1942]. Neurology 2001;57:481-8.
47. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57:489-95.
48. Nunez M, Hasselbalch S, Heun R, Kalisvaart CJ, Kozubski W, Sakka P, et al. Donepezil-treated Alzheimer's disease patients with apparent initial cognitive decline demonstrate significant benefits when therapy is continued: results from a randomised, placebo-controlled trial. Poster presented at the Second Annual Dementia Congress, 12-14 September 2003, Washington, DC, 2003.
49. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer's disease. Neurology 2004; 63:214-19.
50. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, et al. The effects of donepezil in Alzheimees disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-44.
51. Rogers SL, Farlow MR, Doody RS, Mobs R, Friedboff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-45.
52. Rogers SL, Doody RS, Mobs RC, Friedhoff LT, Alter M, Apter J, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998; 158:1021-31.
53. Rogers SL, Friedhoff LT, Apter JT, Richter RW, Hartford JT, Walshe TM, et al. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303.
54. Greenberg SM, Tennis MK, Brown LB, Gomez-Isla T, Hayden DL, Schoenfeld DA, et al. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 2000; 57(9):1380.
55. Seltzer B, et al. [Commercial confidential information removed] A 24-week, multicenter, randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil hydrochloride (E2020) in patients with early Alzheimer's disease. Industry submission, 2004.
56. Wimo A, Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial [published erratum appears in Dement Geriatr Cogn Disord. 2003;16:102]. Dement Geriatr Cogn Disord 2003; 15:44-54.
57. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65.
58. Rösler M, Anand R, Cicin SA, Gauthier S, Agid Y, Dal Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318:633-40.
59. Agid Y, Dubois B, Anand R, Gharabawi G. Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Curr Ther Res Clin Exp 1998;59:837-45.
60. Forette F, Anand R, Gharabawi G. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine. Eur J Neurol 1999;6:423-9.
61. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD. A 6-month randomised, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-8.
62. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589-95.
63. Tariot P, Solomon PR, Morris J, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomised, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-76.
64. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. BMJ 2000;321:1445-9.
65. Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2001;16:852-7.
66. Wilkinson D, Lilienfeld S, Truyen L. Galantamine improves activities of daily living in patients with a1zheimer's disease: a 3 month placebo-controlled study. In Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, Stockholm, 5-8 April 2000. p. 233.
67. Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry 2004;161:532-8.
68. Fuschillo C, La Pia S, Campana F, Pinto A, De Simone L. Cognitive deficits in Alzheimer's disease: Treatment with acetylcholinesterase inhibitor agents. Arch Gerontol Geriatr 2001;7: 151-8.
69. Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002;56:441-6.
70. Jones RW, Soininen H, Hager K, Aarsland D, Passmore P, Murthy A, et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 2004;1:58-67.
71. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24.
72. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41.
73. Larson E. Galantamine improved cognition and global functioning in vascular dementia or Alzheimer disease with cerebrovascular disease. ACP J Club 2002;137(3):102.
74. Wolfson C, Moride Y, Perrault A, Momoli F, Demers L, Oremus M. Drug treatments for Alzheimer's disease: 1. A comparative analysis of clinical trials. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2000.
75. Livingston G, Katona C. How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease: a number needed to treat analysis. Int J Geriatr Psychiatry 2000;15:203-7.
76. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. In The Cochrane Library, Issue 1. Chichester: John Wiley; 2004.
77. Birks J, Grimley EJ, Iakovidou V, Tsolaki M. Rivastiginine for Alzheimer's disease. In The Cochrane Library, Issue 1, Chichester: John Wiley; 2004.
78. Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, et al. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness. Clin Ther 2002;24:862-86.
79. Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 2001;(4). Chichester: John Wiley.
80. Areosa SA, Sherriff F. Memantine for dementia. In The Cochrane Library, Issue 1. Chichester: John Wiley; 2004.
81. Stein K. Donepezil in the treatment of mild to moderate senile dementia of the Alzheimer type (SDAT). Development and Evaluation Committee Report, 69. Bristol: NHS Executive South and West; 1997.
82. Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil. Int J Geriatr Psychiatry 1998;13:445-53.
83. Lanctǒt K, Oh P, Risebrough N. Cost-benefit analysis of cholinesterase inhibitors (ChEI) in Alzheimer's disease (AD). In One-hundredth Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, 18-20 March 1999. San Antonia, TX: 1999;(2):169.
84. Jönsson L, Lindgren P, Witno A, Jönsson B, Winblad B. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clin Ther 1999; 21:1230-40.
85. O'Brien BJ, Goerce R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, et al. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc 1999;47:570-8.
86. Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 1999;52:1138-45.
87. Ikeda S, Yamada Y, Ikegami N. Economic evaluation of donepezil treatment for Alzheimer's disease in Japan. Dement Geriatr Cogn Disord 2002; 13:33-9.
88. Sobolewski M, Kuzniar J, Splawinski J. Is donepezil cost-effective in the treatment of Alzheimer's disease? Neurobiol Aging 2002;23:368.
89. Fagnani E, Lafinna A, Pechevis M, Rigaud AS, Traykov L, Seux ML, et al. Donepezil for the treatment of mild to moderate Alzheimer's disease in France: economic implications. Dement Geriatr Cogn Disord 2003;17:5-13.
90. Stein K. Rivastigmine (Exelon) in the treatment of senile dementia of the Alzheimer type (SDAT). Development and Evaluation Committee Report, 89. Bristol: NHS Executive South and West; 1998.
91. Fenn P, Gray A. Estimating long term cost savings from treatment of Alzheimer's disease: a modelling approach. Pharmacoeconomics 1999; 16:165-74.
92. Hauber AB, Gnanasakthy A, Snyder EH, Bala MV, Richter A, Mauskopf JA. Potential savings in the cost of caring for Alzheimer's disease - treatment with rivastigmine. Pharmacoeconomics 2000;17:351-60.
93. Hauber AB, Gnanasakthy A, Mauskopf JA. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine. Clin Ther 2000;22:439-51.
94. Brooks E, Deal L. The effect of rivastigmine on the direct and indirect costs of Alzheimer's disease. Value in Health 2000;3:79.
95. Getsios D, Caro JJ, Caro G, Ishak K, AHEAD Study Group. Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada. Neurology 2001;57:972-8.
96. Garfield FB, Getsios D, Caro JJ, Wimo A, Winblad B. Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden. Pharmacoeconomics 2002; 20:629-37.
97. Caro JJ, Salas M, Ward A, Getsios D, Mehnert A. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in The Netherlands. Dement Geriatr Cogn Disord 2002;14:84-9.
98. Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O'Brien JA, Papadopoulos G, et al. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clin Ther 2003;25:1806-25.
99. Ward A, Caro JJ, Getsios D, Ishak K, O'Brien J, Bullock R, et al. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. Int J Geriatr Psychiatry 2003;18:740-7.
100. Guilhaume C. Cost effectiveness of memantine in the treatment of moderately severe and severe Alzheimer's disease in Finland. Eur J Neurol 2003; 10(Suppl 1):159-60.
101. Launois R, Guilhame C, Francois C, Maehlum E. Cost effectiveness of memantine in the treatment of moderately severe and severe alzheimer's disease in Norway. International Conference on Alzheimer's and Parkinson's Diseases. Seville; 2003.
102. Antonanzas F, Badenas J, Francois C, Guilhaume C. Cost effectiveness of memantine in the treatment of moderately severe and severe Alzheimer's disease in Spain. Value Health 2003; 6:765.
103. François C, Sintonen H, Sulkava R. The cost-effectiveness of memantine in moderately severe to severe Alzheimer's disease. A Markov model in Finland. Clin Drug Invest 2004;27:373-84.
104. Jones R, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging 2004; 21:607-20.
105. Foster RH, Plosker GL. Donepezil. Pharmacoeconomic implications of therapy. Pharmacoeconomics 1999;16:99-114.
106. Lamb HM, Goa KL. Rivastigmine - a pharmacoeconomic review of its use in Alzheimer's disease. Pharmacoeconomics 2001;19:303-18.
107. Lyseng-Williamson K, Plosker GL. Galantamine: a pharmacoeconomic review of its use in Alzheimer' s disease. Pharmacoeconomics 2002;20:919-42.
108. Shukla VK, Otten N, Coyle D. Drug treatments for Alzheimer's disease. III. A review of pharmacoeconomic evaluations. Technology Report 11. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2000. pp. 1-39.
109. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. A review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technology Assess 2004;8(36).
110. Neumann PJ, Kuntz KM, Leon J, Araki SS, Hermann RC, Hsu MA, et al. Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers. Med Care 1999;37:27-32.
111. Ely M, Melzer D, Opit L, Brayne C. Estimating the number and characteristics of people with cognitive disability in local populations. Res Policy Planning 1996;14(2):13-18.
112. Burns A, Forstl H. The Institute of Psychiatry Alzheimer's disease cohort: part I - clinical observations. Int J Geriatr Psychiatry 1996;11:309-20.
113. Burns A, Forstl H. The Institute of Psychiatry Alzheimer's disease cohort: part II - clinicopathological observations. Int J Geriatr Psychiatry 1996;11:321-7.
114. Hogan DB, Thierer DE, Ebly EM, Parhad IM. Progression and outcome of patients in a Canadian dementia clinic. Can J Neurol Sci 1994; 21:331-8.
115. Helmer C, Letenneur L, Dartigues J. Longévité des déments. Démences et longévité. Paris: Fondation Nationale de Gérontologie; 1997. pp. 111-22 (in French).
116. Letenneur L, Dequae L, Jacqmin H, Nuissier J, Decamps A, Barberger-Gateau P, et al. Prevalence of dementia in Gironde (France). Rev Epidemiol Santé Publ 1993;41:139-45 (in French).
117. Obadia Y, Rotily M, Degrand-Guillaud A, Guelain J, Ceccaldi M, Severo C, et al. The PREMAP Study: prevalence and risk factors of dementia and clinically diagnosed Alzheimer's disease in Provence, France. Prevalence of Alzheimer's Disease in Provence. Eur J Epidemiol 1997; 13:247-53.
118. Kavanagh S, Schneider J, Knapp M, Beecham J, Netten A. Elderly people with cognitive impairment: costing possible changes in the balance of care. Health Soc Care Commun 1993; 1:69-80.
119. Schneider J, Kavanagh S, Knapp M, Beecham J, Netten A. Elderly people with advanced cognitive impairment in England: resource use and costs. Ageing Soc 1993;13:27-50.
120. Kavanagh S, Schneider J, Knapp M, Beecham J, Netten A. Elderly people with dementia: cost effectiveness and balance of care. In Knapp M, editor. The economic evaluation of mental health care. Aldershot: Arena; 1995. pp. 125-56.
121. Stewart A. Costs of care for people with dementia aged 75 and over. Discussion paper 1303/2. University of Kent, Canterbury: PSSRU; 1997.
122. Wolstenholme J, Fenn P, Gray A, Keene J, Jacoby R, Hope T. Estimating the relationship between disease progression and cost of care in dementia. Br J Psychiatry 2002;181:36-42.
123. Bowie P, Branton T, Holmes J. Should the mini mental state examination be used to monitor dementia treatments? Lancet 1999;354:1527-8.
124. Davey RJ, Jamieson S. The validity of using the mini mental state examination in NICE dementia guidelines.J Neurol Neurosurg Psychiatry 2004; 75:343-4.
125. Tombaugh TN, Mcintyre NJ. The mini-mental-state-examination - a comprehensive review. J Am Geriatr Soc 1992;40:922-35.
126. Gray A, Fenn P. Alzheimer's disease: the burden of the illness in England. Health Trends 1993;25:31-7.
127. Monitoring alzheimer's disease in nursing homes. 046/911. London: Taylor Nelson AGB; 1997.
128. Mendiondo MS, Ashford JW, Kryscio Rj, Schmitt EA. Modelling mini mental state examination changes in Alzheimer's disease. Stat Med 2000; 19:1607-16.
129. Martin DC, Miller JK, Kapoor W, Arena VC, Boller F. A controlled study of survival with dementia [published erraturn appears in Arch Neurol 1988;45:619. Arch Neurol 1987;44:1122-6.
130. Netten A, Darton R, Bebbington A, Forder J, Brown P, Mummery K. Residential and nursing home care of elderly people with cognitive impairment: prevalence, mortality and costs. Aging Ment Health 2001;5:14-22.
131. Caro JJ, Getsios D, Migliaccio-Walle K, Raggio G, Ward A. Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care. Neurology 2001;57:964-71.
132. Stern Y, Tang MX, Albert MS, Brandt J, Jacobs DM, Bell K, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease.JAMA 1997;277:806-12.
133. Richards M, Marder K, Bell K, Dooneief G, Mayeux R, Stern Y. Interrater reliability of extrapyramidal signs in a group assessed for dementia. Arch Neurol 1991;48:1147-9.
134. Martin J, Meltzer H, Elliot D. The prevalence of disability among adults. OPCS surveys of disability in Great Britain Report 1. London: HMSO; 1988.
135. Doraiswamy PM, Bieber F, Kaiser L, Krishnan KR, Reuning-Scherer J, Gulanski B. The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology 1997; 48:1511-17.
136. Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, et al. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review. Int J Technol Assess Health Care 2002; 18:497-507.
137. Husereau D, Wolfson C, Shukla V. Drug treatments for Alzheimer's disease: efficacy, outcome measurements and cost effectiveness. Technol Overview 2001;(4).
138. Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer's disease. Clin Ther 1998;20:838-50.
139. Fillit H, Gutterman EM, Lewis B. Donepezil use in managed Medicare: effect on health care costs and utilization. Clin Ther 1999;21:2173-85.
140. Lanctot K, Risebrough N, I. Factors affecting the economic attractiveness of cognitive enhancers in Alzheimer's disease. Annual Meeting of the Canadian Society for Clinical Investigation, the Royal College of Physicians and Surgeons of Canada and Participating Societies Toronto, Ontario, Canada, September 1998. Clin Invest Med 1998;24-27(Suppl):SI7.
141. Tariot P, Federoff HJ. Current treatment for Alzheimer disease and future prospects. Alzheimer Dis Assoc Disord 2003; 17(Suppl 4):S105-113.
142. Mackell JA, Ferris SH, Mobs R, Schneider L, Galasko D, Whitehouse P, et al. Multicenter evaluation of new instruments for Alzheimer's disease clinical trials: summary of results. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11:Suppl-9.
143. Rahkonen T, Eloniemi-Sulkava U, Rissanen S, Vatanen A, Viramo, P, Sulkava R. Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J Neurol Neurosurg Psychiatry 2003;74:720-4.
144. Paton J, Johnston K, Katona C, Livingston G. What causes problems in Alzheimer's disease: attributions by caregivers. Int J Geriatr Psychiatry in press.
145. Kronborg Andersen C, Sogaard J, Hansen E, Kragh-Sorensen A, Hastrup L, Andersen J, et al. The cost of dementia in Denmark: the Odense Study. Dement Geriatr Cogn Disord 1999;10:295-304.
146. Livingston G, Katona C, Roch B, Guilhame C, Rive B. A dependency model for patients with Alzheimer's disease: its validation and relationship to the costs of care - the LASER-AD Study. Curr Med Res Opin 2004;S7:1007-16.
147. Wuno A, Winblad B, Stoffler A, Wirth Y, Mobius HJ. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 2003; 21:327-40.
148. Kronborg Andersen C, Nielsen H, Lolk A, Andersen J, Becker I, Kragh-Sorensen P. Incidence of very mild to severe dementia and Alzheimer's disease in Denmark: the Odense Study. Neurology 1999;52:85-90.
149. Bloom BS, de Pouvourville N, Straus WL. Cost of illness of Alzheimer's disease: how useful are current estimates? Gerontologist 2003;43:158-64.
150. British National Formulary, No. 49 (March). London: British Medical Association and the Royal Pharmaceutical Society of Great Britain; 2005.
151. Department of Health. NHS Reference Costs 2002. URL: http://www.doh.gov.uk/nhsexec/refcosts.htm
152. O'Shea E, O'Reilly S. The economic and social cost of dementia in Ireland. Int J Geriatr Psychiatry 2000;15:208-18.
153. Stewart A. Donepezil in the treatment of people with Alzheimer's disease. a pilot Markov approach. Discussion paper 1324. PSSRU; 1997.
154. Blackwell J, O'Shea E, Moane G, Murray P Care provision and cost measurement: dependent elderly people at home and in geriatric hospitals. Dublin: Economic and Social Research Institute; 1992.
155. Hope T, Keene J, Fairburn C, McShane R, Jacoby R. Behaviour changes in dementia. 2: Are there behavioural syndromes? Int J Geriatr Psychiatry 1997;12:1074-8.
156. Hope T, Keene J, Gedling K, Cooper S, Fairburn C, Jacoby R. Behaviour changes in dementia. 1: Point of entry data of a prospective study. Int J Geriatr Psychiatry 1997;12:1062-73.
157. Morris JN, Fries BE, Mehr DR, Hawes C, Phillips C, Mor V, et al. MDS Cognitive Performance Scale J Gerontol 1994;49:M174-82.
158. Souêtre E, Thwaites RM, Yeardley HL. Economic impact of Alzheimer's disease in the United Kingdom. Cost of care and disease severity for non-institutionalised patients with Alzheimer's disease. Br J Psychiatry 1999;174:51-5.
159. NHS funded nursing care in nursing homes: what it means for you. URL: www.doh.gov.uk/joint/unit/freenursingcare/residentscarersguide.pdf. Accessed 2004.
160. Alzheimers Society. Paying home care fees. Information Sheet. London: Alzheimers Society; 2004.
161. Whitehouse P. Measurements of quality of life in dementia. In Wimo A, jonsson B, Karlsson G, Winblad B, editors. Health economics of dementia. Chichester: John Wiley; 1998. pp. 403-17.
162. Walker MD, Salek SS, Bayer AJ. A review of quality of life in Alzheimer's disease. Part 1: Issues in assessing disease impact. Pharmacoeconomics 1998; 14:499-530.
163. Leon J, Neumann PJ, Hermann RC, Hsu M-A, Cummings JL, Doraiswamy PM, et al. Health-related quality-of-life and service utilization in Alzheimer's disease: a cros s-sectional study. Am J Alzheimer's Dis 2000;15:94-108.
164. Neumann P, Sandberg EA, Araki SS, Kuntz KM, Feeny D, Weinstein MC. A comparison of HU12 and HU13 utility scores in Alzheimer's disease. Med Decis Making 2000;20:413-22.
165. Torrance GW, Feeny DH, Furlon WJ, Barr RD, Zhang Y, Wang Q. Multi-attribute preference functions for a comprehensive health status classification system: Health Utilities Index Mark 2. Med Care 1996;24:702-22.
166. Neumann PJ. Measuring QALYS in dementia. In Wimo A, Jonsson B, Karlsson G, Winblad B, editors. Health economics of dementia. Chichester: John Wiley; 1998. pp. 359-70.
167. Zimmerman SJ, Magaziner J. Methological issues in measuring the functional status of cognitively impaired nursing home residents: the use of proxies and performance based measures. Alzheimer Dis Assoc Disord 1994;8(Suppl 1):281-90.
168. Kerner DN, Patterson TL, Grant I, Kaplan RM. Validity of the quality of well-being scale for patients with Alzheimer's disease. J Aging Health 1998;10:44-61.
169. Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Serv Res 1988;23:203-35.
170. Sano M, Albert SM, Tractenberg R, Schittini M. Developing utilities: quantifying quality of life for stages of Alzheimer's disease as measured by the Clinical Dementia Rating. J Ment Health Aging 1999;5:59-68.
171. Dodge HH, Shen C, Pandav R, DeKosky ST, Ganguli M. Functional transitions and active life expectancy associated with Alzheimer disease. Arch Neurol 2003;60:253-9.
172. Burns A, Lewis G, Jacoby R, Levy R. Factors affecting survival in Alzheimer's disease. Psychol Med 1991;21:363-70.
173. Newcomer R, Covinsky KE, Clay T, Yaffe K. Predicting 12-month mortality for persons with dementia.J Gerontol B Mychol Sci Soc Sci 2003; 58:S187-98.
174. Hui JS, Wilson RS, Bennett DA, Bienias JL, Gilley DW, Evans DA. Rate of cognitive decline and mortality in Alzheimer's disease. Neurology 2003;61:1356-6 1.
175. Lapane KL, Gambassi G, Landi F, Sgadari A, Mor V, Bernabei R. Gender differences in predictors of mortality in nursing home residents with AD. Neurology 2001;56:650-4.
176. Aneshensel CS, Pearlin LI, Levy-Storms L, Schuler RH. The transition from home to nursing home mortality among people with demenfia. J Gerontol B Psychol Sci Soc Sci 2000;55:SI52-62.
177. Mitchell SL, Kiely DK, Hamel MB, Park PS, Morris JN, Fries BE. Estimating prognosis for nursing home residents with advanced dementia. JAMA 2004;291:2734-40.
178. Clark CM, Sheppard L, Fillenbaurn G, Galasko D, Morris JC, Koss E, et al. Variability in annual minimental state examination score in patients with probably Alzheimer's disease. Arch Neurol 1999; 56:857-62.
179. Neumann PJ, Araki SS, Arcelus A, Longo A, Papadopoulos G, Kosik KS, et al, Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD. Neurology 2001;57:957-64.
180. Monis JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaurn G, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989; 39:1159-65.
181. Mendiondo MS, Kryscio RJ, Schmitt EA. Models of progression in AD: predicting disability and costs [comment]. Neurology 2001;57:943-4.
182. BBC News. Britons ignoring dementia signs. 2004.
183. Wilkinson D, Stave C, Keohane D, Vincenzino O. The role of general practitioners in the diagnosis and treatment of Alzheimer's disease: a multinational survey. J Int Med Res 2004;32:149-59.
184. Williams A. The measurement and valuation of health. A chronicle. Discussion Paper 136. York: University of York Centre for Health Economics; 1995.
185. Kavanagh S, Knapp M. Costs and cognitive disability: modelling the underlying associations. Br J Psychiatry 2002; 180:120-5.
186. Kavanagh S, Knapp M. Cognitive disability and direct care costs for elderly people. Br J Psychiatry 1999;174:539-46.
187. Neumann, Hermann RC, Weinstein MC. Measuring QALYs in dementia. In Wimo A, Jonsson B, Karlsson G, Winblad B, editors. Health economics of dementia. Chichester: John Wiley; 1998.
188. McDaid D. Estimating the costs of informal care for people with Alzheimer's disease: methodological and practical challenges. Int J Geriatr Pychiatry 2001;16:400-5.
189. Department of Health. Prescription cost analysis 2003. URL: http://www.dh.gov.uk/PublicationsAndStatistics/Publications/ PublicationsStatistics/. Accessed 2004.
190. The European Agency for the Evaluation of Medicinal Products. Note for guidance on medicinal products in the treatment of Alzheimer's disease. London: CPMP; 1997.
191. Holmes C, Lovestone S. Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. Age Ageing 2003; 32:200-4.
192. Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, Zhu Y, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 2003;20:777-89.
193. Jonsson L, Lindgren P, Wimo A, Jonsson B, Winblad B. Costs of mini mental state examination-related cognitive impairment. Pharmacoeconomics 1999;16:409-16.
194. Statistic yearbook. Stockholm: Statistica Centralbyrån; 1995.
195. Canadian study of health and aging: study methods and prevalence of dementia. CMAJ 1994; 150:899-913.
196. Rice DP, Fox PJ, Max W, Webber PA, Lindeman DA, Hauck WW, et al. The economic burden of Alzheimer's disease care. Health Aff (Millwood) 1993;12:164-76.
197. Ernst RL, Hay JW, Fenn C, Tinklenberg J, Yesavage JA. Cognitive ftinction and the costs of Alzheimer disease: an exploratory study. Arch Neurol 1997;54:687-93.
198. Hux MJ, O'Brien BJ, Iskedjian M, Goeree R, Gagnon M, Gauthier S. Relation between severity of Alzheimer's disease and costs of caring. CMAJ 1998;159:457-65.